Indication
Familial hyperkalemic periodic paralysis
Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults. Read more about Familial hyperkalemic periodic paralysis
5 drugs 5 manufacturers
Drugs that treat it
Common Familial hyperkalemic periodic paralysis therapies.
KEVEYIS (dichlorphenamide)
ORMALVI (dichlorphenamide)
DICHLORPHENAMIDE
DICHLORPHENAMIDE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonFamilial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults.
It is classically caused by gain-of-function mutations in the *SCN4A* gene encoding the voltage-gated skeletal muscle sodium channel Nav1.4, which lead to impaired channel inactivation, sustained sarcolemmal depolarization, and temporary loss of muscle fiber excitability.
Clinically, the condition is defined by recurrent, transient episodes of flaccid muscle weakness or paralysis that are frequently accompanied by elevated serum potassium concentrations and subclinical or clinical myotonia.
Episodes typically involve the proximal limbs and are commonly triggered by rest following strenuous physical exertion, fasting, cold exposure, or potassium-rich dietary intake.
- nih.gov
Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults Clinically, the condition is defined by recurrent, transient episodes of flaccid muscle weakness or paralysis that are frequently accompanied by elevated serum potassium concentrations and subclinical or clinical myotonia
- medlineplus.gov
Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults It is classically caused by gain-of-function mutations in the *SCN4A* gene encoding the voltage-gated skeletal muscle sodium channel Nav1.4, which lead to impaired channel inactivation, sustained sarcolemmal depolarization, and temporary loss of muscle fiber excitability
- wikipedia.org
Familial hyperkalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy that primarily affects skeletal muscle function in children and adults It is classically caused by gain-of-function mutations in the *SCN4A* gene encoding the voltage-gated skeletal muscle sodium channel Nav1.4, which lead to impaired channel inactivation, sustained sarcolemmal depolarization, and temporary loss of muscle fiber excitability Clinically, the condition is defined by recurrent, transie...
- nih.gov
It is classically caused by gain-of-function mutations in the *SCN4A* gene encoding the voltage-gated skeletal muscle sodium channel Nav1.4, which lead to impaired channel inactivation, sustained sarcolemmal depolarization, and temporary loss of muscle fiber excitability
- medlineplus.gov
Clinically, the condition is defined by recurrent, transient episodes of flaccid muscle weakness or paralysis that are frequently accompanied by elevated serum potassium concentrations and subclinical or clinical myotonia Episodes typically involve the proximal limbs and are commonly triggered by rest following strenuous physical exertion, fasting, cold exposure, or potassium-rich dietary intake
- brainfacts.org
Episodes typically involve the proximal limbs and are commonly triggered by rest following strenuous physical exertion, fasting, cold exposure, or potassium-rich dietary intake
Personalize your experience
Follow Familial hyperkalemic periodic paralysis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.